BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37517087)

  • 1. The integration of machine learning and multi-omics analysis provides a powerful approach to screen aging-related genes and predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Shen J; Gao H; Li B; Huang Y; Shi Y
    Aging (Albany NY); 2023 Jul; 15(14):6848-6864. PubMed ID: 37517087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
    Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
    BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
    Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
    BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
    Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
    Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Yang L; Zhang W; Yan Y
    Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning-based prognostic modeling of lysosome-related genes for predicting prognosis and immune status of patients with hepatocellular carcinoma.
    Li W; Wang Q; Lu J; Zhao B; Geng Y; Wu X; Chen X
    Front Immunol; 2023; 14():1169256. PubMed ID: 37275878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
    Hong T; Su W; Pan Y; Tian C; Lei G
    Front Immunol; 2022; 13():951459. PubMed ID: 36189258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.
    Gao B; Wang Y; Lu S
    Sci Rep; 2023 Jan; 13(1):1137. PubMed ID: 36670201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integration of multi-omics analysis and machine learning for the identification of prognostic assessment and immunotherapy efficacy through aging-associated genes in lung cancer.
    Lu W; Zhou Y; Zhao R; Liu Q; Yang W; Zhu T
    Aging (Albany NY); 2024 Jan; 16(2):1860-1878. PubMed ID: 38261733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential biomarkers for the prognosis and treatment of HCC immunotherapy.
    Li H; He Q; Zhou GM; Wang WJ; Shi PP; Wang ZH
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2027-2046. PubMed ID: 36930502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
    Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
    Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma.
    Liu T; Li C; Zhang J; Hu H; Li C
    Front Immunol; 2023; 14():1237350. PubMed ID: 37575252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.
    Sun L; Wu Z; Dong C; Yu S; Huang H; Chen Z; Wu Z; Yin X
    BMC Med Genomics; 2023 Jun; 16(1):130. PubMed ID: 37316840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
    Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
    Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.
    Shi Y; Feng Y; Qiu P; Zhao K; Li X; Deng Z; Wang J
    Front Immunol; 2023; 14():1298290. PubMed ID: 38170006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.